Simon Westbrook
Chief Scientific Officer Levicept
Simon has a strong track record of innovation and delivery of drug development programmes with 30 years of drug discovery and development experience, including 15 years at Pfizer Sandwich UK. Simon has played pivotal roles in progressing novel, successful projects from conception of idea to delivery of clinical data. Simon is the named inventor on numerous patents, including p75NTR-Fc for the treatment of pain. He was a team member of four programmes that achieved positive readout in proof-of-concept phase II clinical trials and SGLT-2 inhibitor STEGLATROM which is marketed for treatment of Type II diabetes.
Seminars
Wednesday 28th January 2026
Transforming Osteoarthritis Care: LEVI-04 as a Next-Generation Non- Opioid Analgesic
9:00 am
- Mode of action of LEVI-04 as a first-in-class disease-modifying agent for osteoarthritis (OA)
- Safety & efficacy data from a 500-patient Phase 2 clinical study; findings, conclusions and learnings to take forward
- Insights into chronic pain in OA and the role of bone marrow lesions
